:''..Ivermectin is not approved by the FDA for the treatment of any viral infection.. ..Ivermectin has been shown to inhibit replication of SARS-CoV-2 in cell cultures. However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.. ..The primary outcomes of these trials showed that the use of ivermectin for the treatment of COVID-19 had no clinical benefit. In TOGETHER, an adaptive platform trial conducted in Brazil, there was no apparent difference between the ivermectin and placebo arms for the primary outcome of risk of emergency department visits or hospitalization (14.7% vs. 16.4%). Also, there was no statistically significant difference between the ivermectin and placebo arms in mortality (3.1% vs. 3.5%)... ..Recommendation - The Panel recommends against the use of ivermectin for the treatment of COVID-19, except in clinical trials..''<ref>https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/</ref> | :''..Ivermectin is not approved by the FDA for the treatment of any viral infection.. ..Ivermectin has been shown to inhibit replication of SARS-CoV-2 in cell cultures. However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.. ..The primary outcomes of these trials showed that the use of ivermectin for the treatment of COVID-19 had no clinical benefit. In TOGETHER, an adaptive platform trial conducted in Brazil, there was no apparent difference between the ivermectin and placebo arms for the primary outcome of risk of emergency department visits or hospitalization (14.7% vs. 16.4%). Also, there was no statistically significant difference between the ivermectin and placebo arms in mortality (3.1% vs. 3.5%)... ..Recommendation - The Panel recommends against the use of ivermectin for the treatment of COVID-19, except in clinical trials..''<ref>https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/</ref> |